Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ophthotech Corp    OPHT

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : to Present at the Morgan Stanley Global Healthcare Conference

09/17/2015 | 06:42pm US/Eastern

By a News Reporter-Staff News Editor at Clinical Trials Week -- Ophthotech Corporation (NASDAQ:OPHT) announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 16, 2015 at 8:45 a.m. ET (see also Ophthotech Corporation).

Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech's website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will be available for 14 days following the presentation. About Ophthotech Corporation Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD. For more information, please visit www.ophthotech.com. Forward-looking Statements Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so. View source version on businesswire.com: http://www.businesswire.com/news/home/20150909005105/en/

Keywords for this news article include: Ophthotech Corporation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC

(c) 2015 NewsRx LLC, source Health Newsletters

React to this article
Latest news on OPHTHOTECH CORP
09/17 OPHTHOTECH : to Present at the Morgan Stanley Global Healthcare Conference
09/10 OPHTHOTECH : Entry into a Material Definitive Agreement (form 8-K)
09/09 OPHTHOTECH : to Present at the Morgan Stanley Global Healthcare Conference
09/02 OPHTHOTECH : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08/13 MIDATECH PHARMA : Signs Deal With Eye Disesases Company Ophthotech
08/12 OPHTHOTECH : Reports Second Quarter 2015 Financial and Operating Results
08/05 OPHTHOTECH : reports 2Q loss
08/05 OPHTHOTECH : Results of Operations and Financial Condition, Financial Statements..
08/05 OPHTHOTECH : Reports Second Quarter 2015 Financial and Operating Results
08/05 OPHTHOTECH : Reports Second Quarter 2015 Financial and Operating Results
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Income Statement Evolution
More Financials